Cara Therapeutics | CARA - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Acadia Pharmaceuticals USD 26.32M 18.28M 2025-12
Alterity Therapeutics Limited AUD -4.74M 3.53M 2024-12
Assertio Holdings USD -2.88M 648K 2024-09
Cara Therapeutics USD -4.91M 3.17M 2025-03
Cassava Sciences USD -10.81M 33.41M 2025-09
Chugai Pharma JPY 169.9B 13.83B 2025-12
Cipla INR 11.69B 6.85B 2025-12
Clal Biotechnology ILS 86.82M 17.9M 2022-12
Compugen USD 56.84M 63.78M 2025-12
CSL USD 2.61B 1.21B 2025-12
Grifols EUR 257.85M 190.87M 2024-12
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
J&J USD 4.97B 2.53B 2025-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Pacira USD 9.52M 11.45M 2025-09
Pfizer USD 3.33B 290M 2025-09
RedHill Biopharma USD -1.54M 12M 2024-06
Supernus Pharmaceuticals USD -1.91M 56.04M 2025-12
Vanda Pharmaceuticals USD -22.92M 16.68M 2024-12